Combination of intravitreal injection of ranibizumab and laser photocoagulation for the treatment of retinopathy of prematurity / 眼科新进展

ABSTRACT

Objective To evaluate the efficacy and safety of the treatment of retinopathy of premature (ROP) using laser photocoagulation (LP) and intravitreal injection ranibizumab (IVR).Methods Totally 32 infants (64 eyes) with ROP underwent IVR,followed by observation of the regression of the plus diseases,ridges,neovascularization on the ridge and the development of peripheral retinal vessels.Besides,12 patients (24 eyes) of 32 infants whose plus diseases,ridges and neovascularization on the ridge did not still improve continued to undergo LP.Results In the 64 eyes,the lesions completely disappeared by IVR in 40 eyes,accounting for 62.5％,and the recurrence in 24 eyes was recovered by combined laser photocoagulation,accounting for 37.5％.Among the 24 eyes with recurrent lesions,14 eyes were aggressive posterior retinopathy of prematurity (AP-ROP),6 eyes were ROP at threshold stage,and 4 eyes were pre-threshold ROP.All infants with retinal lesions improved to some degree.Intravitreal injection of ranibizumab could approach neovascular and hemorrhagic absorption,and vascular development to serrate or scar lesions.And 24 eyes of recurrence lesions were improved after photocoagulation;no ocular or the systematic adverse reactions were observed.Conclusion Intravitreal injection of ranibizumab for the treatment of ROP can achieve satisfied outcomes;as for the infants without satisfied outcomes,retinal laser photocoagulation can be performed.